Aspiriant LLC trimmed its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 6.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,572 shares of the biopharmaceutical company’s stock after selling 520 shares during the quarter. Aspiriant LLC’s holdings in Bristol-Myers Squibb were worth $428,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. ProShare Advisors LLC increased its stake in Bristol-Myers Squibb by 8.4% during the 2nd quarter. ProShare Advisors LLC now owns 338,422 shares of the biopharmaceutical company’s stock valued at $14,055,000 after purchasing an additional 26,267 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 14.1% during the second quarter. EverSource Wealth Advisors LLC now owns 5,695 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 703 shares during the last quarter. Public Sector Pension Investment Board increased its position in shares of Bristol-Myers Squibb by 71.2% during the second quarter. Public Sector Pension Investment Board now owns 77,950 shares of the biopharmaceutical company’s stock valued at $3,237,000 after acquiring an additional 32,407 shares in the last quarter. Magnetar Financial LLC purchased a new position in Bristol-Myers Squibb in the 2nd quarter worth approximately $636,000. Finally, Xponance Inc. boosted its stake in Bristol-Myers Squibb by 8.8% during the 2nd quarter. Xponance Inc. now owns 317,381 shares of the biopharmaceutical company’s stock valued at $13,181,000 after purchasing an additional 25,543 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Bristol-Myers Squibb
In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This represents a 5.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Samit Hirawat acquired 1,830 shares of Bristol-Myers Squibb stock in a transaction dated Friday, November 1st. The shares were bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the transaction, the executive vice president now owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on BMY
Bristol-Myers Squibb Stock Up 1.3 %
BMY stock opened at $57.01 on Wednesday. The business’s 50-day moving average price is $57.46 and its 200-day moving average price is $52.20. The stock has a market cap of $115.63 billion, a P/E ratio of -15.88, a PEG ratio of 1.98 and a beta of 0.45. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.08. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The business had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company’s revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.00 earnings per share. On average, equities research analysts forecast that Bristol-Myers Squibb will post 0.92 EPS for the current year.
Bristol-Myers Squibb Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a dividend of $0.62 per share. The ex-dividend date is Friday, January 3rd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a yield of 4.35%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -69.08%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Read More
- Five stocks we like better than Bristol-Myers Squibb
- Why is the Ex-Dividend Date Significant to Investors?
- SAP’s Strong Momentum: A Bullish Setup for Investors
- Stock Market Sectors: What Are They and How Many Are There?
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Why Invest in High-Yield Dividend Stocks?
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.